of treatment for those patients is autologous stem cell transplantation (ASCT) after intensive salvage chemotherapy. Ideally, salvage chemotherapy should achieve complete metabolic remission (CR) since this is favorable when aiming for long-term control of disease. 2 Commonly used salvage chemotherapy regimens like ICE (ifosfamide, carboplatin, and etoposide), DHAP (cisplatin, cytarabine, and dexamethasone), and ESHAP (etoposide, steroids, ara-C, and cisplatin) yield CR rates of between 20% and 50% and are associated with significant toxicities. [3] [4] [5] Recently, a phase 1/2 trial by Garcia-Sanz et al investigated the addition of brentuximab vedotin (BV) to ESHAP in patients with relapsed or refractory cHL as induction therapy before planned ASCT. The combination showed improved efficacy when indirectly compared to ESHAP alone while still being tolerable. 6 BV in combination with other chemotherapy agents (doxorubicin, vinblastine, and dacarbazine) also has already been shown to be superior to standard chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in the frontline treatment of advanced HL in the ECHELON-1 trial. 7 Two-phase 1/2 studies by LaCasce et al 8 and O'Connor et al 9 in 2018 showed that therapy with BV could achieve high CR rates as salvage therapy and was still effective in heavily pretreated patients, while having manageable side effects when indirectly compared to platinum-based therapies. A phase 2 study by Friedberg et al 10 , comparing BV and bendamustine to BV in combination with dacarbazine as frontline therapy in patients over the age of 60, also showed a very high efficacy of bendamustine and BV (100% ORR, 88% CR), albeit associated with a significantly higher toxicity in these patients.
While the encouraging efficacy of bendamustine and BV has been shown in Hodgkin lymphoma, and BV in combination with other chemotherapy agents has already been proven effective and safe in the frontline treatment of CD30 positive PTCL, 11 Due to the paucity of data, we therefore wanted to assess the efficacy and safety of a bendamustine and BV regimen and its suitability as induction therapy before high-dose chemotherapy and subsequent ASCT in clinical practice, in unselected patients with Hodgkin lymphoma and PTCL, who were in part heavily pretreated.
| PATIENTS AND ME THODS

| Patients
First, we identified patients with cHL and PTCL treated with bendamustine and BV from the Austrian Brentuximab Vedotin registry of the Austrian Study Group of Medical Tumor Therapy (AGMT) (415-E/1942). Then, we added patients from two additional tertiary Austrian cancer centers to achieve sufficient patient numbers.
Overall, we identified 28 patients with histologically confirmed cHL and five patients with PTCL, which were treated with a combination of bendamustine (70 or 90 mg/m 2 on day 1 and 2 of 3-week cycles) and BV (1.8 mg/kg on day 1 of 3-week cycles) between 2015 and 2019. One patient received prophylactic G-CSF. Treatments were chosen at the discretion of the treating institutions, and all patients signed an informed consent form agreeing to being treated with an off-label regimen. Clinical characteristics and outcome were retrospectively analyzed by chart-based review. Assessment of response was done according to the Lugano FDG-PET/CT criteria. 13 
| Statistical analysis
Clinical characteristics, progression-free survival (PFS), and overall survival (OS) after therapy with bendamustine and BV were retrospectively analyzed by chart-based review. PFS was defined as the time from start of treatment until disease progression or death from any cause. OS was defined as the time from treatment start until death from any cause. All statistical analyses were performed using IBM ® SPSS ® statistics software, version 24. Kaplan-Meier curve analysis was used for estimation of survival.
| RE SULTS
| Patients with classical Hodgkin lymphoma
| Patient characteristics and outcome
The detailed patient characteristics can be found in Table 1 . As expected, patients with cHL were younger than the patients with PTCL (median age 43.5 vs 70 years, P = .01) and most of them had a good performance status, with only two patients (7.1%) having an ECOG score higher than one. Eighteen patients (64.3%) were male, and The overall response rate (ORR) in all patients was 100%. For 22 patients (78.6%), achievement of a CR after completion of chemotherapy was documented and six patients (21.4%) achieved a partial remission. The rate of CR and PR in only those 24 patients with relapsed or refractory cHL was 75.0% and 25.0%, respectively.
| Use as an induction therapy before autologous stem cell transplantation
In thirteen patients (46.4%), bendamustine and BV were used as planned induction therapy before high-dose chemotherapy (HDT) 
| Adverse events
The most frequently documented adverse events were skin events (in 39.03% of patients), infusion-related reactions (in 35.7% of patients), and infections requiring intervention or hospitalization (in 35.7% of patients). Notably, only one patient was administered prophylactic G-CSF from the start of therapy and further three patients were administered G-CSF in consecutive cycles after developing severe neutropenia.
Therapy discontinuation due to the severity of adverse events affecting the skin was not necessary in any patient, as only mild and moderate events occurred. Three patients (10.7%) developed peripheral polyneuropathy during treatment, one of which had to discontinue therapy because of it. Administration of the next treatment cycle had to be delayed due to side effects at least once in 21.4% of patients, and in 28.6% of patients, the bendamustine dose had to be lowered due to toxicities. One patient died in partial remission 9 weeks after last chemotherapy due to unknown reasons, which we counted as therapy related. No other deaths occurred during therapy.
| Patients with peripheral T-cell lymphoma
We collected data of five patients with PTCL-two PTCL NOS, one Table 2 . the ORR of the 37 included patients was 78%, with 43% complete responses. Patients in the trial had a median of three previous therapies before receiving bendamustine and BV, possibly explaining the lower response rate. The phase 1-2 trial by LaCasce et al 8 , in which all 53 enrolled patients received bendamustine and BV as first salvage therapy, showed an ORR of 93%, with 74% of patients achieving a CR, which is very similar to our results. The 1-year PFS of 80% was also similar to the 81.9% 1-year PFS we calculated for our patients.
| D ISCUSS I ON
The toxicities reported in our analysis were also in line with other studies, consisting mostly of infusion-related reactions, adverse events affecting the skin and infections. 8, 9 As always in retrospective studies, assessment of adverse events is hampered by incomplete and not standardized documentation. Therefore, we used extensions of the planned intervals between treatment cycles and reductions of drug doses during treatment as surrogate markers for toxicities, leaving us with a rate of around 20% events leading to dose reduction, delay of therapy administration or discontinuation of therapy, which is a realistic assumption when compared with other published data. Friedberg et al 10 reported a markedly more pronounced toxicity of bendamustine and BV in patients over the age of 60. We can also confirm the higher mortality during treatment of older patient, as the patient dying due to treatment toxicity was over the age of 70.
In contrast to most other studies, bendamustine and BV were also given as first-line therapy in four patients; one of them changing to bendamustine and BV due to significant toxicities of treatment with BEACOPPesc. Friedman et al 10 also analyzed bendamustine and BV or dacarbazine and BV as frontline treatment in elderly patients over the age of 60 with cHL. In that study, the combination of bendamustine and BV resulted in a superior ORR of 100% with 88% of patients achieving CR, albeit with a significantly higher toxicity.
Since the number of patients we treated in a first-line setting was low and neither the rate of response, nor the 1-year PFS or OS did chemotherapy mainly due to progression or toxicity and further 6% did not proceed to ASCT due to various reasons. 14 In another trial, single-agent BV was used in patients with relapsed and refractory Hodgkin lymphoma. While the treatment was well tolerated and 89% of patients were able to proceed to ASCT, the ORR to BV was 68%, with only 35% of patients achieving a CR. 15 In conclusion, salvage therapy with bendamustine and BV before ASCT seems to be better tolerable than traditional therapy with DHAP, while resulting in an excellent response rate, which is reflected in 100% of our patients intended to undergo ASCT actually proceeding to ASCT after therapy.
Concerning the feasibility of stem cell collection during or after receiving bendamustine-containing chemotherapy, we did not run the treated patients. 16, 17 We therefore conclude that stem cell mobilization is feasible during the early cycles of therapy with bendamustine and brentuximab or after therapy in most patients.
The two relapses of cHL after ASCT in our 13 patients were observed in one patient refractory to BEACOPP and the other one underwent ASCT late as fourth salvage therapy. Apart from these two relapses of disease, two other relevant clinical events occurred so far: one patient who also received bendamustine and BV as fifthline therapy was primary refractory to the combination treatment, and one patient died due to treatment toxicity. We therefore suspect that high age being refractory to previous therapies and later treatment lines seem to be associated with a worse prognosis.
Only one patient with PTCL has been included in prospective clinical studies investigating a combination of bendamustine and BV so far, 9 but the effectivity of monotherapy with either substance has been demonstrated in previous studies. Patients with relapsed or refractory PTCL treated with single-agent bendamustine showed an ORR of 50%, with 28% of patients in CR. 18 Single-agent BV therapy in patients with relapsed or refractory CD30+ PTCL resulted in an ORR of 41%, with a CR rate of 24%. 19 However, the duration of response to single-agent bendamustine or BV is short, and therefore, new treatment combinations are needed. In the ECHELON-2 trial, patients with CD30+ PTCL were treated with either BV and cyclophosphamide, doxorubicin, and prednisone (A+CHP) or cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), showing that the BV including regimen was more effective and well tolerable. 11 Dumont et al treated nine patients with PTCL with bendamustine and BV, observing a CR in two patients and a PR in further five patients. We therefore decided for off-label use in the five patients described in our analysis and observed a response in 60% of patients, with all three patients responding to therapy achieving a CR, lasting for 5, 20, and 21 months, respectively. Two patients were still in CR at time of data collection, one patient had a relapse of disease.
Notably, only two patients with PTCL did not respond to treatment with bendamustine and BV. Further clinical data are still needed to assess the efficacy of bendamustine and BV in patients with PTCL, but our results are promising when compared to historical data.
Limitations of our study include the retrospective nature of the study design, the not standardized and possibly incomplete documentation of adverse events in some patients and the relatively small number of patients. One major limitation of our study is the lack of long-term follow-up. The heterogeneity of our patient population regarding number and type of previous therapy and other patient characteristics complicates the comparison to other data, but resembles clinical practice.
In conclusion, a combination of bendamustine and BV is a highly effective salvage therapy for patients with relapsed or refractory cHL and can be efficiently used as induction therapy before HDT and subsequent ASCT, due to the high number of complete responses. The side effects are usually well manageable and a high rate of patients intended to undergo ASCT can do so. However, special caution must be taken when treating older patients with this combination. Further studies with a higher number of patients are needed to directly compare the efficacy of this treatment to other options for salvage therapy.
Further studies are also needed to evaluate the possible use and efficiency of bendamustine and BV in patients with PTCL compared to other treatment regimens. 
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